Evidence map›Paper›PMID 35451488›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.

Luis M Ruilope, Bertram Pitt, Stefan D Anker, Peter Rossing, Csaba P Kovesdy, Roberto Pecoits-Filho, Pablo Pergola, Amer Joseph, Andrea Lage, Nicole Mentenich and 2 more

2 registry-linked trialsOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02545049 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.

TypeinterventionalSponsorBayerRan2015 to 2021Enrolled7,352ConditionsDiabetic Kidney DiseaseArmsFinerenone (BAY94-8862), Placebo
NCT06835322 phase2completednot on this mapstarted 2025, after this paper: background citation

Effect of Finerenone on Proteinuria and GFR Progression in Patients With Non Diabetic Glomerulonephritis: A Randomized Clinical Trial

TypeinterventionalSponsorAlexandria UniversityRan2025 to 2026Enrolled100ConditionsGlomerulonephritisArmsFinerenone, Placebo
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 5 countries.

Luis M RuilopeCardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain.
Bertram PittDepartment of Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Stefan D AnkerDepartment of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Peter RossingSteno Diabetes Center Copenhagen, Gentofte, Denmark.ORCID 0000-0002-1531-4294
Csaba P KovesdyDivision of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.ORCID 0000-0002-8204-911X
Roberto Pecoits-FilhoArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Pablo PergolaRenal Associates, PA, San Antonio, TX, USA.
Amer JosephResearch and Development, Cardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany.
Andrea LageCardiology and Nephrology Clinical Development, Bayer SA, São Paulo, Brazil.
Nicole MentenichStatistics and Data Insights, Bayer AG, Wuppertal, Germany.
Markus F ScheererGlobal Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.
George L BakrisDepartment of Medicine, University of Chicago Medicine, Chicago, IL, USA.
Bayer (Germany) · DECentro de Investigación en Red en Enfermedades Cardiovasculares · ESGerman Centre for Cardiovascular Research · DEPontifícia Universidade Católica do Paraná · BRRenal Associates P. A. · USUniversity of Chicago · USUniversity of Copenhagen · DKUniversity of Michigan · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1-4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in patients with advanced CKD. This analysis further explores kidney outcomes in FIGARO-DKD.

methodsFIGARO-DKD (NCT02545049) included patients with urine albumin-to-creatinine ratio (UACR) 30-<300 mg/g and estimated glomerular filtration rate (eGFR) 25-90 mL/min/1.73 m2 or UACR 300-5000 mg/g and eGFR ≥60 mL/min/1.73 m2. Outcomes included two composite kidney endpoints, a composite of ≥40% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death, and a composite of ≥57% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death. Changes in albuminuria and eGFR slope were also analyzed. Kidney and CV outcomes were evaluated by baseline UACR.

resultsA lower incidence rate for the eGFR ≥40% kidney composite endpoint was observed with finerenone compared with placebo, but the between-group difference was not significant [hazard ratio (HR) = 0.87; 95% confidence interval (CI): 0.76-1.01; P = .069]. A greater treatment effect was observed on the eGFR ≥57% kidney composite endpoint (HR = 0.77; 95% CI: 0.60-0.99; P = 0.041) with a 36% relative risk reduction for end-stage kidney disease. A larger magnitude of effect on kidney outcomes was observed with finerenone versus placebo for patients with severely increased albuminuria than with moderately increased albuminuria. Improvements in UACR, eGFR slope and cardiovascular risk were evident in both subgroups with finerenone.

conclusionsThe present analyses suggest that finerenone protects against kidney disease progression and cardiovascular events in patients with T2D and early- or late-stage CKD.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Renal Insufficiency, ChronicAlbuminuriaGlomerular Filtration RateHumansKidneyNaphthyridinesfinerenoneNaphthyridinesalbuminuriachronic kidney diseasefinerenonekidney outcomestype 2 diabetes

Identifiers

PMID35451488
PMCPMC9923706
OpenAlexW4224248430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.